There are currently no direct head-to-head clinical trials evaluating bortezomib-melphalanprednisone (VMP) versus lenalidomide and low-dose dexamethasone (Rd). VMP (257 cases) and Rd (222 cases) arms of two randomized phase III trials were employed to assess the treatment influence on outcome in untreated elderly MM patients.
| I N T R O D U C T I O N
Currently, the combinations of bortezomib, melphalan (M), and prednisone (P) (VMP) or MP and thalidomide (T) (MPT) represent the standard of care for untreated multiple myeloma (MM) patients over 65 years of age. 1 The VISTA trial showed that VMP was superior to MP, with risk reductions in progression (52%) and in death (31%). [2] [3] [4] Other large randomized trials confirmed the efficacy and safety of this schedule in this setting of patients. [5] [6] [7] [8] Moreover, a reduced intensity schedule (once-weekly) of bortezomib 7, 8 and its subcutaneous administration 9 allowed a reduction in the incidence of peripheral neuropathy without any negative impact on efficacy. Recently, our group showed the superiority of VMP on MPT through a case-matched study in elderly untreated MM patients enrolled in six randomized trials. 10 More recently, three phase III randomized trials have shown the safety and efficacy of the combination of lenalidomide and low-dose dexamethasone (Rd) as first line therapy for elderly MM patients. [11] [12] [13] Based on the results of one of these trials (FIRST MM-020) 11 No randomized trial comparing VMP versus Rd has been performed to date. In this analysis, we compared patient data, over a 60-month follow-up period, from two randomized phase III trials with the aim of assessing the impact of treatment on outcome as well as the effect modification by time on the treatment-outcome relationship in elderly untreated MM patients receiving VMP or Rd. and NCT01093196, 13 respectively.
| M E T H O D S

| Assessment
The following data were collected at each participating center, sent to a centralized coordinating center, reviewed for consistency and com- Responses were assessed using IMWG criteria. 14 
| Statistical analysis
Patients were analyzed on an intention-to-treat basis for all timeto-event end points. OS was defined as the time from study entry to death due to any cause, PFS as the time from study entry until progression or death due to myeloma; in both cases, patients still alive were censored at the date of last contact.
PFS and OS rates were estimated using the method of KaplanMeier. 15 PFS and OS survival curves for VMP and Rd arms were compared using the log-rank test. Univariate and multiple Cox regression models were used to assess the effect of covariates on PFS and OS. 
| R E S U LTS
Baseline characteristics were well-balanced between the two groups, although a significantly higher percentage of cases with worse ECOG performance status and with elevated creatinine value were present in the VMP group, while a significantly higher rate of elderly patients (age 75 years) were observed in the Rd group (Table 1) .
| Response rate
Four patients in the VMP (2 for physician choice, 1 for withdrawal of consent, and 1 for progressive disease) and ten in the Rd (5 for screening failure, 2 for death, 2 for withdrawal of consent and 1 for second primary malignancy) did not receive any chemotherapy and were excluded from the response and safety analyses.
After induction therapy the overall response rate (at least partial response, PR) was higher, although still not statistically significant, in the VMP arm: 81% with VMP and 74% with Rd (P 5 0.074). While a statistically greater proportion of patients in the VMP group had a CR (VMP vs. Rd: 24% vs. 3%; P < .0001; Table 2 ). The rate of VGPR was similar in the two arms (VMP vs. Rd: 26 vs. 31%; P 5 .25; Table 2 ). The analysis of the effect of study drugs on OS showed that the HR of VMP versus RD for OS was quite homogenous throughout time (Figure 2 ; no time by treatment interaction was found) and the higher efficacy of VMP as compared to Rd was maintained also after data adjustment for potential confounders (Supporting Information Table   S1b ). Again, a Cox analysis performed in the subgroup of patients with available cytogenetic risk data (n 5 369) showed that the effect of VMP versus Rd remained significant (HR: 0.64, 95% CI: 0.41-1.00, P 5 .05) also by adjusting for cytogenetic risk.
| Survival analysis
| Frequency of AEs
Rates of treatment-related death were similar between the VMP and Rd group: 7 patients (3%) died in the VMP group and 10 (4%) in the Rd. Likewise, the two groups did not differ significantly in the discontinuation rates due to AEs: 42/257 (17%) in the VMP group and 30/ 212 (14%) in the Rd. Supporting Information Table S2 lists the grade
3-4 AEs during induction. The incidence of any grade 3-4 hematologic
AEs was significantly higher in the VMP arm (41 vs. 29%; P 5 .009).
Severe anemia (10 vs. 4%; P 5 .031) and severe thrombocytopenia (20 vs. 7%; P < .0001) were more frequent with treatment by VMP.
While, the rate of severe neutropenia was similar in the two groups (28% in the VMP group and 25% in the Rd). The rate of nonhematologic AEs was 33% in VMP and 30% in Rd patients. A significantly higher rate of grade 3-4 sensory neuropathy and/or neuralgia was reported in VMP cases (12 vs. 2%; P < .0001). While, the distribution of other nonhematological grade 3-4 AEs was similar in the two groups. The incidence of severe infections was 9% in both arms.
| DISCUSSION
In the absence of available randomized clinical trials directly comparing MPT versus VMP, our group performed a case-matched study on elderly untreated MM patients enrolled in six randomized trials, demonstrating the superiority of VMP over MPT. 10 Similarly, there are currently no direct head-to-head clinical trials evaluating Rd versus VMP.
In this study, we compared patient data from VMP and Rd arms of two randomized phase III trials with the aim of assessing the impact of the specific treatment on outcome in elderly untreated MM patients.
In this retrospective analysis data, 479 patients (257 receiving VMP and 222 Rd) were analyzed. Over a pre-defined 60-months follow-up period, VMP was associated with a significantly higher CR rate and with a trend toward significance for ORR. VMP was also associated with a significant reduced risk of progression for the first 12 months after therapy start. After this period and up to 32 months follow-up no statistically significant differences in terms of PFS were observed between the two schedules; vice versa, after 32 months, Rd showed a statistically significant benefit in PFS. These results are likely related to the ability for deeper tumor shrinkage (higher CR rate) by VMP than Rd approach allowing a longer PFS initially, while the Rd schedule, overcomes this evident initial hitch in reducing the tumor burden, through long term drug administration (continuous therapy), thus obtaining a subsequent better disease control. Nevertheless, although a late advantage in terms of PFS has been observed for Rd, VMP was associated with a significant longer OS. In order to interpret these data we should consider that most patients treated with VMP in first line received lenalidomide-containing regimens in second line and vice-versa. Thus, we can speculate that, in light of available data regarding clonal evolution in MM, the V-R sequence seems to be more effective in controlling the emergence of resistant clones compared with R-V. Moreover, we must also consider that the Rd group consisted of a significantly higher number of elderly patients, although this is offset by the fact that the VMP group is characterized by a significantly higher number of cases with worse ECOG performance status and impaired renal function.
Furthermore, despite evident limitations due to missing data, the VMP schedule allowed to overcome the negative impact of high cytogenetic risk on PFS.
Both the toxicity profiles of VMP and Rd and treatment-related deaths were quite similar in the two groups. The overall incidence of grade 3-4 hematologic AEs was significantly higher in VMP patients, especially the incidence of thrombocytopenia. The incidence of grade 3-4 sensory neuropathy and/or neuralgia was significantly higher in the VMP group. Subcutaneous bortezomib could further improve the drug toxicity profile. . 17 The results of our study are only partially in line with those reported in Weisel's network meta-analysis because we found, using an effect-modification analysis having time as an effect modifier, that Rd is superior to VMP only after 32 months of follow-up.
However, an effect modification promoted by a potential effectmodifier can only be studied when individual data is available, and for this reason, it is not testable on aggregated data such as those used in a network meta-analysis, which assumes, by definition, no interaction with time. Furthermore, despite the growing use of network metaanalysis in many fields of medicine, several issues need to be addressed to avoid conclusions that are inaccurate, invalid, or not clearly justified. VMP could theoretically be preferred to Rd considering that most of the emerging second-line three-drug protocols contain Rd as backbone, foreseeing a potential reduced efficacy for patients already exposed to an IMID. However, the treatment effect, as evaluated by HRs, is generally consistent regardless of prior treatment with a proteasome inhibitor, which is quite expected, or IMID across all recent protocols, in which new proteasome inhibitors 18, 19 or monoclonal antibodies 20, 21 were combined with Rd. In the light of our results, we can speculate that an induction with a bortezomib-containing regimen followed by maintenance with an IMiD may provide the best long-term outcome.
Finally, the use of the VMP schedule in clinical practice should be considered mainly for patients with a significant tumor mass who need a relatively rapid reduction, as well as for those patients with renal impairment and at high cytogenetic risk. Conversely, Rd also finds wide therapeutic application especially in the remaining patients or in cases where patients may face difficulties in reaching the hospital for treatment.
In conclusion, given the limits of this analysis, such as heterogeneity in the patient population and the lack of relevant data (postrelapse treatment and comorbidity) this is the first direct comparison between the two schedules. In light of our results, Rd seems to be associated to better PFS in the long term, while VMP seems to be linked to a longer OS. Both therapeutic approaches show an acceptable toxicity profile.
Nonetheless, this head-to-head retrospective study of the two schedules may help physicians make a more informed therapy choice.
